P
Philipp Karschnia
Researcher at Ludwig Maximilian University of Munich
Publications - 69
Citations - 1046
Philipp Karschnia is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 39 publications receiving 476 citations. Previous affiliations of Philipp Karschnia include Harvard University & Saarland University.
Papers
More filters
Journal ArticleDOI
The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.
Sven Diederichs,Sven Diederichs,Lorenz Bartsch,Julia C. Berkmann,Karin Fröse,Jana Heitmann,Caroline Hoppe,Deetje Iggena,Danny Jazmati,Philipp Karschnia,Miriam Linsenmeier,Thomas Maulhardt,Lino Möhrmann,Johannes Morstein,Stella V Paffenholz,Paula Röpenack,Timo Rückert,Ludger Sandig,Maximilian Schell,Anna Steinmann,Gjendine Voss,Jacqueline Wasmuth,Maria E Weinberger,Ramona Wullenkord +23 more
TL;DR: C coding‐independent mutations can affect gene regulation from transcription, splicing, mRNA stability to translation, and hence, this largely neglected area needs functional studies to elucidate the mechanisms underlying tumorigenesis.
Journal ArticleDOI
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia,Philipp Karschnia,Justin T. Jordan,Deborah Forst,Isabel Arrillaga-Romany,Tracy T. Batchelor,Joachim M. Baehring,Nathan F. Clement,L. Nicolas Gonzalez Castro,Aline Herlopian,Marcela V. Maus,Michaela H. Schwaiblmair,Jacob D. Soumerai,Ronald W. Takvorian,Ephraim P. Hochberg,Jeffrey A. Barnes,Jeremy S. Abramson,Matthew J. Frigault,Jorg Dietrich +18 more
TL;DR: It was found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity, and high pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival.
Journal ArticleDOI
CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Kai Rejeski,Ariel Perez Perez,Pierre Sesques,Eva Hoster,Carolina Berger,Liv Jentzsch,Dimitrios Mougiakakos,L. Frölich,Josephine Ackermann,Veit Buecklein,Viktoria Blumenberg,Christian Schmidt,Laurent Jallades,Boris Fehse,Christoph Faul,Philipp Karschnia,Oliver Weigert,Martin Dreyling,Frederick L. Locke,Michael von Bergwelt-Baildon,Andreas Mackensen,Wolfgang Bethge,Francis Ayuk,Emmanuel Bachy,Gilles Salles,Michael D. Jain,Marion Subklewe +26 more
TL;DR: The CAR-HEMATOTOX model, which included markers associated with hematopoietic reserve, implicates pre-CART bone marrow reserve and inflammatory state as key features associated with delayed cytopenia and will be useful for risk-adapted management of hematotoxicity.
Journal ArticleDOI
Pharmacologic management of cognitive impairment induced by cancer therapy.
TL;DR: Large clinical trials for putative memory-enhancing drugs have emerged as promising compounds in the management of cognitive dysfunction, but clinical experience of their use remains limited and large clinical trials are needed to establish their clinical value in an oncology setting.
Journal ArticleDOI
Evidence-based recommendations on categories for extent of resection in diffuse glioma.
Philipp Karschnia,Michael A. Vogelbaum,Martin J. van den Bent,Daniel P. Cahill,Lorenzo Bello,Yoshitaka Narita,Mitchel S. Berger,Michael Weller,Joerg-Christian Tonn +8 more
TL;DR: In this article, the authors developed evidence-based expert recommendations on categories for extent of resection based on a comprehensive literature review, and formulated for the categories "biopsy", "partial resection", "subtotal resection" and "supramaximal resection".